Replies to post #108012 on Anavex Life Sciences Corp (AVXL)

[frrol]

That didn't answer OFP's question and in fact reinforced his point. But it is a tough question that we don't have the answer to yet. Missling suspects 2-73 has higher relative S1 selectivity as an allosteric, with the only other confirmed effect being its modulation of two of the muscarinic receptors, which he thinks may be providing some synergistic benefit.

[OFP]

None of those sigma-1 agonists fix mitochondria.

Well they do have positive effects at the mitochondria but do they "fix" them, no. As a result, 2-73 which is proposed to have the same MOA but weaker action, lower S1R binding affinity would not be expected to either.

Sigma-1 agonism is not the central factor; rather, it's Anavex's unique sigma-1 agonist that uniquely restores neuron homeostasis (normal biochemical function). There may be many other sigma-1 agonists; but none of them demonstrate restoration of neuron homeostasis. None of them restore normal mitochondrial function. None of them effectively treat Alzheimer's disease. Anavex 2-73 does.

And yet the entire AVXL narrative about homeostasis is built upon the generic S1R agonism mechanism. What about 2-73's action has been shown to be unique?...as far as I can tell just weaker S1R action and lower affinity. Not a great start.